28,800 Shares in GSK PLC Sponsored ADR $GSK Purchased by Sanders Morris Harris LLC

Key Points

• Sanders Morris Harris LLC purchased 28,800 GSK shares worth approximately $1.4 million during the third quarter. Institutional investors and hedge funds collectively own 15.74% of GSK.
• Analysts maintain a broadly cautious outlook, with a consensus “Hold” rating and a $55.33 price target; ratings include four Buys, 12 Holds and three Sells.
• GSK reported quarterly earnings and revenue above expectations and increased its quarterly dividend to $0.4515, equivalent to a 3.8% annualized yield. Recent developments include restructuring-related job cuts, pipeline progress and an $800 million Pennsylvania expansion.

Sanders Morris Harris LLC purchased a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 28,800 shares of the pharmaceutical company's stock, valued at approximately $1,404,000.

Several other institutional investors also recently added to or reduced their stakes in the company. Focus Financial Network Inc. raised its position in GSK by 10.4% in the 3rd quarter. Focus Financial Network Inc. now owns 4,345 shares of the pharmaceutical company's stock valued at $209,000 after purchasing an additional 410 shares during the last quarter. Roberts Wealth Advisors LLC boosted its stake in GSK by 2.3% during the 3rd quarter. Roberts Wealth Advisors LLC now owns 87,733 shares of the pharmaceutical company's stock worth $4,226,000 after purchasing an additional 2,014 shares during the period. B. Riley Wealth Advisors Inc. grew its position in GSK by 4.3% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 8,485 shares of the pharmaceutical company's stock worth $409,000 after purchasing an additional 352 shares during the last quarter. Sax Wealth Advisors LLC purchased a new position in GSK during the 3rd quarter worth $394,000. Finally, HF Advisory Group LLC increased its stake in GSK by 6.7% in the third quarter. HF Advisory Group LLC now owns 8,084 shares of the pharmaceutical company's stock valued at $389,000 after purchasing an additional 506 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on GSK shares. Barclays reissued a "sell" rating on shares of GSK in a report on Monday, September 7th. Deutsche Bank Aktiengesellschaft restated a "neutral" rating on shares of GSK in a research report on Tuesday, September 29th. Jefferies Financial Group reaffirmed a "buy" rating on shares of GSK in a research note on Monday, September 28th. Royal Bank Of Canada initiated coverage on GSK in a research note on Tuesday, September 8th. They set a "sector perform" rating for the company. Finally, Berenberg Bank reaffirmed a "buy" rating on shares of GSK in a research report on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $55.33.

GSK Price Performance

GSK stock traded up $1.65 during trading on Wednesday, reaching $47.92. 7,087,352 shares of the company were exchanged, compared to its average volume of 4,480,969. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The stock's 50 day moving average price is $49.82 and its 200 day moving average price is $51.73. GSK PLC Sponsored ADR has a 52-week low of $42.85 and a 52-week high of $61.69. The company has a market cap of $96.93 billion, a P/E ratio of 14.98, a PEG ratio of 2.11 and a beta of 0.33.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The company had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.02 billion. During the same period last year, the company posted $0.47 earnings per share. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts predict that GSK PLC Sponsored ADR will post 4.78 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were issued a $0.4515 dividend. This represents a $1.81 annualized dividend and a yield of 3.8%. This is a positive change from GSK's previous quarterly dividend of $0.44. The ex-dividend date of this dividend was Friday, August 14th. GSK's dividend payout ratio is currently 55.31%.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Cost savings could support profitability: GSK reportedly plans to eliminate up to 1,217 jobs in Belgium as part of a three-year restructuring program. While the cuts create near-term disruption, investors may view them as a step toward improving efficiency and controlling costs. GSK to cut up to 1,217 jobs in Belgium, L'Echo says
• Positive Sentiment: Pipeline progress: The first patient has been dosed in a GSK and Oxford University trial evaluating a potential treatment for ulcerative colitis. The study adds to the company’s longer-term growth prospects, although clinical and regulatory risks remain. First Patient Dosed in GSK-Oxford Colitis Trial
• Positive Sentiment: Expanded U.S. manufacturing presence: GSK plans to invest $800 million in a Pennsylvania expansion, potentially strengthening domestic production capacity and supporting future operational growth. GSK to invest $800M in Pennsylvania expansion
• Neutral Sentiment: Third-quarter outlook remains broadly steady: RBC Capital Markets expects results to be roughly in line, with weaker vaccine sales offset by strength in HIV medicines and respiratory drug Nucala. RBC maintained its Sector Perform rating and 1,975-pence price target ahead of the October 28 earnings release. GSK third quarter likely to be in line
• Negative Sentiment: Large-scale job cuts highlight restructuring pressure: The Belgian reductions, reportedly affecting more than 1,200 positions at a major vaccine operation, could raise concerns about business momentum, employee relations and execution risk. They also underscore pressure to offset softer vaccine demand. Pharmaceutical giant GSK to eliminate 1,200 jobs in Belgium

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK's portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.